Eva Jack | Chief Business Officer |
Anna Protopapas | Chief Executive Officer |
Tim Lowinger | Chief Scientific Officer |
Dave Spellman | Chief Financial Officer |
Debjit Chattopadhyay | H.C. Wainwright |
Jonathan Chang | Leerink Partners |
Jessica Fye | JPMorgan |
Mike Ulz | Baird |
David Nierengarten | Wedbush Securities |
Good morning and welcome to Mersana Therapeutics’ Third Quarter 2018 Conference Call. Currently, all participants are in listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to turn the call over to the Mersana team. Please proceed.